Bildkälla: Stockfoto

Nanexa: Moments of truth closing in - Redeye

Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nordisk. We believe upcoming events regarding the clinical development of NEX-20 and NEX-22 bode well for the share price development, and that Nanexa’s investment agreement with Novo Nordisk could also generate shareholder value.

Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nordisk. We believe upcoming events regarding the clinical development of NEX-20 and NEX-22 bode well for the share price development, and that Nanexa’s investment agreement with Novo Nordisk could also generate shareholder value.
Börsvärldens nyhetsbrev
ANNONSER